NK cell-mediated anti-leukemia cytotoxicity is enhanced using a NKG2D ligand MICA and anti-CD20 scfv chimeric protein

Yizhou Zou, Weiguang Luo, Jing Guo, Qizhi Luo, Mi Deng Ph.D., Zhigang Lu, Yi Fang, Chengcheng Zhang

Research output: Contribution to journalArticle

1 Scopus citations

Abstract

NK cells are important innate cytotoxic lymphocytes that have potential in treatment of leukemia. Engagement of NKG2D receptor on NK cells enhances the target cytotoxicity. Here, we produced a fusion protein consisting of the extracellular domain of the NKG2D ligand MICA and the anti-CD20 single-chain variable fragment (scfv). This recombinant protein is capable of binding both NK cells and CD20+ tumor cells. Using a human NKG2D reporter cell system we developed, we showed that this fusion protein could decorate CD20+ tumor cells with MICA extracellular domain and activate NK through NKG2D. We further demonstrated that this protein could specifically induce the ability of a NK cell line (NKL) and primary NK cells to lyse CD20+ leukemia cells. Moreover, we found that downregulation of surface HLA class I expression in the target cells improved NKL-mediated killing. Our results demonstrated that this recombinant protein specifically lyses leukemia cells by NK cells, which may lead to development of a novel strategy for treating leukemia and other tumors.

Original languageEnglish (US)
Pages (from-to)1750-1763
Number of pages14
JournalEuropean Journal of Immunology
Volume48
Issue number10
DOIs
StatePublished - Oct 1 2018

    Fingerprint

Keywords

  • CD20
  • Chimeric protein
  • Cytotoxicity
  • MICA
  • NKG2D

ASJC Scopus subject areas

  • Immunology and Allergy
  • Immunology

Cite this